Gemcitabine: In combination with carboplatin in the treatment of recurrent ovarian cancer

American Journal of Cancer

Volumn 4, Issue 5, 2005, Pages 337-344

  Oldfield, Vicki ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CARBOPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPNEA; EDEMA; EUROPE; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GRANULOCYTOPENIA; HEMATOLOGIC MALIGNANCY; HEMATURIA; HUMAN; INFECTION; LEUKOPENIA; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINURIA; RASH; REVIEW; SENSORY NEUROPATHY; SOLID TUMOR; STATISTICAL SIGNIFICANCE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT OUTCOME; VOMITING;

EID: 27644538459     PISSN: 11756357     EISSN: 11756357     Source Type: Journal    
DOI: 10.2165/00024669-200504050-00011     Document Type: Review

References (42)

1. American Cancer Society Inc. Cancer facts & figures [online]. Available from URL: http://www.cancer.org [Accessed 2005 Sep 7]
2. Herzog TJ. Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004; 10 (22): 7439-49
3. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54 (1): 8-29
4. National Comprehensive Cancer Network. Ovarian cancer guideline [online]. Available from URL: http://www.nccn.org [Accessed 2005 Jun 2]
5. Sehouli J. Review of gemcitabine-based combinations for platinum-resistant ovarian cancer. Int J Gynecol Cancer 2005 May; 15 Suppl. 1: 23-30
6. Eisenhauer EA, Vermorken JB, van Glabbeke M. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997 Oct; 8: 963-8
7. Alvarez AA, Clarke-Pearson DL. Platinum-resistant and refractory ovarian cancer: second-line treatment options. Am J Cancer 2003; 2 (1): 1-13
8. Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist 2002; 7 Suppl. 5: 20-8
9. Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist 2002; 7 Suppl. 5: 11-9
10. Gemzar® (gemcitabine hydrochloride): summary of product characteristics. Eli Lilly Sweden AB, 2004 Mar 19
11. Gemzar® (gemcitabine hydrochloride): product information. Indianapolis (IN): Eli Lilly and Company, 2004 May 19
12. Bookman MA. Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinic. Int J Gynecol Cancer 2005 May; 15 Suppl. 1: 12-7
13. Cappella P, Tomasoni D, Faretta M, et al. Cell cycle effects of gemcitabine. Int J Cancer 2001 Aug 1; 93 (3): 401-8
14. Ruiz van Haperen VWT, Veerman G, Noordhuis P, et al. Concentration and time dependent growth inhibition and metabolism in vitro by 2′,2′- difluoro-deoxycy-tidine (gemcitabine). Adv Exp Med Biol 1991; 309A: 57-60
15. Ruiz van Haperen VWT, Veerman G, Boven E, et al. Schedule dependence of sensitivity to 2′,2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours. Biochem Pharmacol 1994; 48 (7): 1327-39
16. Boven E, Schipper H, Erkelens CAM, et al. The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer. Br J Cancer 1993 Jul; 68: 52-6
17. Braakhuis BJM, Ruiz van Haperen VWT, Boven E, et al. Schedule-dependent antitumor effect of gemcitabine in in vivo model systems. Semin Oncol 1995 Aug; 22 (4 Suppl. 11): 42-6
18. Bauknecht T, Einzmann T, Brandstetter T, et al. The cell cycle arrest and apoptosis in ovarian cancer cells exposed to cisplatin and gemcitabine are p53 dependent, in cells exposed to taxol p53 independent [abstract]. Gynecol Oncol 1997 Feb; 64: 313
19. Cartee L, Kucera GL. Gemcitabine induces programmed cell death and activates protein kinase C in BG-1 human ovarian cancer cells. Cancer Chemother Pharmacol 1998 Apr; 41: 403-12
20. Cloven NG, Kyshtoobayeva A, Burger RA, et al. In vitro chemoresistance and biomarker profiles are unique for histologic subtypes of epithelial ovarian cancer. Gynecol Oncol 2004 Jan; 92 (1): 160-6
21. Williams J, Lucas PC, Griffith KA, et al. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease. Gynecol Oncol 2005 Feb; 96 (2): 287-95
22. Ruiz van Haperen VWT, Veerman G, Eriksson S, et al. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine- resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 1994 Aug 1; 54 (15): 4138-43
23. Peters GJ, Ruiz van Haperen VWT, Bergman AM, et al. Preclinical combination therapy with gemcitabine and mechanisms of resistance. Semin Oncol 1996 Oct; 23 Suppl. 10 (5): 16-24
24. Bergman AM, Pinedo HM, Talianidis I, et al. Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines. Br J Cancer 2003 Jun 16; 88 (12): 1963-70
25. Bajetta E, Stani SC, De Candis D, et al. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 2003; 14: 242-7
26. Edelman MJ, Quam H, Mullins B. Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol 2001; 48: 141-4
27. Smith JA, Brown J, Martin MC, et al. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 2004; 92 (1): 314-9
28. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines. Adv Exp Med Biol 1994; 370: 139-43
29. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996 Mar; 2: 521-30
30. Van Moorsel CJ, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines. Br J Cancer 1999 Jun; 80 (7): 981-90
31. Moufarij MA, Phillips DR, Cullinane C. Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines. Mol Pharmacol 2003 Apr; 63 (4): 862-9
32. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9 (3): 491-8
33. Grunewald R, Abbruzzese JL, Tarassoff P, et al. Saturation of 2′,2′-difluorodeoxycitidine 5′-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 1991; 27: 258-62
34. Carmichael J, Allerheiligen S, Walling J, et al. A phase I study of gemcitabine and carboplatin in non-small cell lung cancer. Semin Oncol 1996; 23 Suppl. 10 (5): 55-9
35. Pfisterer J, Vergote I, Du Bois A, et al. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005 May; 15 Suppl. 1: 36-41
36. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer: results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG [abstract no. 5005 plus oral presentation]. 40th Annual Meeting of the American Society of Clinical Oncology; 2004 Jun 5-8; New Orleans (LA)
37. Kose MF, Sufliarsky J, Beslija S, et al. A phase II study of gemcitabine plus carboplatin in platinum-sensitive, recurrent ovarian carcinoma. Gynecol Oncol 2005 Feb; 96 (2): 374-80
38. Papadimitriou CA, Fountzilas G, Aravantinos G, et al. Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group Study. Gynecol Oncol 2004 Jan; 92 (1): 152-9
39. du Bois A, Luck HJ, Pfisterer J, et al. Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer: a dose-finding study by the Arbeitsgemein-schaft Gynakologische Onkologie (AGO) Ovarian Cancer Study Group. Ann Oncol 2001 Aug; 12: 1115-20
40. Alvarez RD, Orlando M, Mannel RS, et al. Three-arm phase I study of fixed-dose rate (FDR) gemcitabine (Gem) + carboplatin (Cb) in relapsed, platinum sensitive (Pt-S) ovarian cancer (OC) patients (pts): results of the first cohort [abstract no. 482P]. Ann Oncol 2004; 15 Suppl. 3: 129. Plus poster presented at the 29th European Society for Medical Oncology; 2004 Oct 29-Nov 2; Vienna
41. Green MR. Gemcitabine safety overview. Semin Oncol 1996; 23: 32-5
42. Mayne Pharma plc. Carboplatin 10 mg/mL intravenous infusion. Summary of product characteristics [online]. Available from URL: http://www.emc.medicines. org.uk [Accessed 2005 Jun 29]